SEC Comment Letter 0000000000-25-003070 to Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc.
Date: March 21, 2025 · CIK: 0001788028 · Accession: 0000000000-25-003070
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285914
Letter
Re: Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed March 19, 2025 File No. 333-285914 Dear Ronald Martell:
March 21, 2025
Ronald Martell President and Chief Executive Officer Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City, CA 94065
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Samantha H. Eldredge, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 21, 2025 Ronald Martell President and Chief Executive Officer Jasper Therapeutics, Inc. 2200 Bridge Pkwy Suite #102 Redwood City, CA 94065 Re: Jasper Therapeutics, Inc. Registration Statement on Form S-3 Filed March 19, 2025 File No. 333-285914 Dear Ronald Martell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Samantha H. Eldredge, Esq. </TEXT> </DOCUMENT>